Pentagastrin
A synthetic pentapeptide analogue of gastrin used diagnostically to stimulate gastric acid secretion and test the function of parietal cells, helping diagnose conditions such as pernicious anemia and Zollinger-Ellison syndrome. It is also used to stimulate calcitonin secretion as a provocative test for medullary thyroid carcinoma.
Molekularmasse
767,9000 g/mol
LogP
1,50
TPSA
276,00 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Therapeutische Bereiche
Wirkmechanismus
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
InChI
InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1
Molecular Formula
C37H49N7O9S
HBD / HBA
8 / 10
Rotierbare Bindungen
22
Schwere Atome
54
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A synthetic pentapeptide analogue of gastrin used diagnostically to stimulate gastric acid secretion and test the function of parietal cells, helping diagnose conditions such as pernicious anemia and Zollinger-Ellison syndrome. It is also used to stimulate calcitonin secretion as a provocative test for medullary thyroid carcinoma.
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Yes, Pentagastrin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1328. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9853654. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pentagastrin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pentagastrin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pentagastrin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pentagastrin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pentagastrin"></drugfyi-drug>